Bitte verwenden Sie diesen Link, um diese Publikation zu zitieren, oder auf sie als Internetquelle zu verweisen: https://hdl.handle.net/10419/66549 
Erscheinungsjahr: 
2010
Quellenangabe: 
[Journal:] Intereconomics [ISSN:] 1613-964X [Volume:] 45 [Issue:] 1 [Publisher:] Springer [Place:] Heidelberg [Year:] 2010 [Pages:] 35-47
Verlag: 
Springer, Heidelberg
Zusammenfassung: 
This article examines a sample of German pharmaceutical firms to highlight the strategic reasons why firms participate in various intellectual property (IP) marketplaces, both proprietary (patents and copyrights) and non-proprietary (open source and non-patented technology). The obstacles that prevent these marketplaces from functioning efficiently are also investigated. The analysis suggests that IP policy must embrace all IP forms and must recognise that IP marketplaces do not work automatically but suffer many institutional failures.
Persistent Identifier der Erstveröffentlichung: 
Dokumentart: 
Article
Dokumentversion: 
Published Version

Datei(en):
Datei
Größe
245.49 kB





Publikationen in EconStor sind urheberrechtlich geschützt.